



MAGLUMI® PIVKA-II (CLIA)

INTENDED USE

The kit is an in vitro chemiluminescence immunoassay for the quantitative determination of PIVKA-II in human serum and plasma using the MAGLUMI series Fully-auto chemiluminescence immunoassay analyzer and Biolumi series Integrated System, and the assay is used for an aid in diagnosis of HCC (hepato-cellular carcinoma), monitoring of high risk patients (hepatitis or cirrhosis, etc.) for development of HCC, and in management of HCC.

SUMMARY

Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), also known as Des-γ-carboxy-prothrombin (DCP)¹, is an abnormal form of prothrombin secreted into the blood.

Prothrombin is primarily synthesized in the liver and has 10 γ-carboxylated glutamic acid (Gla) residues in its N-terminal domain². Under normal conditions, the prothrombin precursor in the liver is post-translationally carboxylated by γ-glutamyl carboxylase to form prothrombin. In the absence of vitamin K or in the presence of vitamin K antagonists, the carboxylation modification process is blocked, and the liver produces abnormal prothrombin³. Because the γ-carboxyglutamic acid is a functional area in calcium-binding, the des-carboxylated prothrombins are functionally defective⁴.

In some cases, Vitamin K deficiency or treatment with a vitamin K antagonist (warfarin or phenprocoumon), PIVKA-II levels may increase^{5,6}. In liver disease and liver malignancy, PIVKA-II can be present even without vitamin K deficiency⁷. Lots of reports have shown elevation in serum PIVKA-II levels in patients with hepatocellular carcinoma and liver cirrhosis⁸⁻¹⁰.

Measurement of PIVKA-II marker levels is clinically useful for aid in the diagnosis and prognosis of patients with HCC and in monitoring HCC patients under therapy^{11,12}. PIVKA-II is an independent predictor of HCC presence¹³. Several studies indicate that PIVKA-II has a better diagnostic value than AFP in differentiating HCC from nonmalignant chronic liver disease. The accuracy, sensitivity, and specificity of PIVKA-II were higher than AFP in management of HCC¹⁴.

TEST PRINCIPLE

Sandwich chemiluminescence immunoassay.

The sample, buffer, magnetic microbeads coated with anti-PIVKA-II monoclonal antibody are mixed thoroughly, incubating and performing a wash cycle after a precipitation in a magnetic field. ABEI labeled with another anti-PIVKA-II monoclonal antibody are then added, reacting to form sandwich complexes and incubating. After precipitation in a magnetic field, the supernatant is decanted and then a wash cycle is performed. Subsequently, the Starter 1+2 are added to initiate a chemiluminescent reaction. The light signal is measured by a photomultiplier as relative light units (RLUs), which is proportional to the concentration of PIVKA-II present in the sample.

REAGENTS

Kit Contents

Component	Description	100 tests/kit	50 tests/kit	30 tests/kit
Magnetic Microbeads	Magnetic microbeads coated with anti-PIVKA-II monoclonal antibody (~10.0 μg/mL) in PBS buffer, NaN ₃ (<0.1%).	2.5 mL	2.0 mL	1.0 mL
Calibrator Low	A low concentration of PIVKA-II antigen in Tris-HCl buffer, NaN ₃ (<0.1%).	2.0 mL	1.5 mL	1.5 mL
Calibrator High	A high concentration of PIVKA-II antigen in Tris-HCl buffer, NaN ₃ (<0.1%).	2.0 mL	1.5 mL	1.5 mL
Buffer	PBS buffer, NaN ₃ (<0.1%).	13.5 mL	8.0 mL	4.8 mL
ABEI Label	ABEI labeled with anti-PIVKA-II monoclonal antibody (~62.5 ng/mL) in PBS buffer, NaN ₃ (<0.1%).	23.5 mL	13.5 mL	7.8 mL
Diluent	0.9% NaCl.	15.0 mL	10.0 mL	10.0 mL
Control 1	A low concentration of PIVKA-II antigen (50.0 mAU/mL) in Tris-HCl buffer, NaN ₃ (<0.1%).	2.0 mL	2.0 mL	2.0 mL
Control 2	A high concentration of PIVKA-II antigen (5000 mAU/mL) in Tris-HCl buffer, NaN ₃ (<0.1%).	2.0 mL	2.0 mL	2.0 mL

All reagents are provided ready-to-use.

The control barcode labels are provided.

Warnings and Precautions

- For *in vitro* diagnostic use.
- For professional use only.
- Exercise the normal precautions required for handling all laboratory reagents.
- Personal protective measures should be taken to prevent any part of the human body from contacting samples, reagents, and controls, and should comply with local operating requirements for the assay.
- A skillful technique and strict adherence to the package insert are necessary to obtain reliable results.
- Do not use kit beyond the expiration date indicated on the label.
- Do not interchange reagent components from different reagents or lots.
- Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).
- All waste associated with biological samples, biological reagents and disposable materials used for the assay should be considered potentially infectious and should be disposed of in accordance with local guidelines.
- This product contains sodium azide. Sodium azide may react with lead or copper plumbing to form highly explosive metal azides. Immediately after disposal, flush with a large volume of water to prevent azide build-up. For additional information, see Safety Data Sheets available for professional user on request.

Note: If any serious incident has occurred in relation to the device, please report to Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) or our authorized representative and the competent authority of the Member State in which you are established.

Reagent Handling

- To avoid contamination, wear clean gloves when operating with a reagent kit and sample. When handling reagent kit, replace the gloves that have been in contact with samples, since introduction of samples will result in unreliable results.
- Do not use kit in malfunction conditions; e.g., the kit leaking at the sealing film or elsewhere, obviously turbid or precipitation is found in reagents (except for Magnetic Microbeads) or control value is out of the specified range repeatedly. When kit in malfunction conditions, please contact Snibe or our authorized distributor.
- To avoid evaporation of the liquid in the opened reagent kits in refrigerator, it is recommended that the opened reagent kits to be sealed with reagent seals contained within the packaging. The reagent seals are single use, and if more seals are needed, please contact Snibe or our authorized distributor.
- Over time, residual liquids may dry on the septum surface. These are typically dried salts and have no effect on assay efficacy.
- Use always the same analyzer for an opened reagent integral.
- For magnetic microbeads mixing instructions, refer to the Preparation of the Reagent section of this package insert.
- For further information about the reagent handling during system operation, please refer to Analyzer Operating Instructions.

Storage and Stability

- Do not freeze the integral reagents.
- Store the reagent kit upright to ensure complete availability of the magnetic microbeads.
- Protect from direct sunlight.

Stability of the Reagents	
Unopened at 2-8°C	until the stated expiration date
Opened at 2-8°C	6 weeks
On-board	4 weeks



0123



130201029M: 100 tests/kit

130601029M: 50 tests/kit

130701029M: 30 tests/kit

Stability of Controls	
Unopened at 2-8°C	until the stated expiration date
Opened at 2-8°C	6 weeks
Opened at 15-25°C	6 hours
Frozen at -20°C	3 months
Frozen and thawed cycles	no more than 3 times

SPECIMEN COLLECTION AND PREPARATION

Specimen Types

Only the specimens listed below were tested and found acceptable.

Specimen Types	Collection Tubes
Serum	Tubes without additive/accessory, or tubes containing clot activator or clot activator with gel
Plasma	K2-EDTA, Li-heparin

- The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. Follow tube manufacturers' instructions carefully when using collection tubes.

Specimen Conditions

- Do not use heat-inactivated samples or grossly hemolyzed/hyperlipidaemia specimens and specimens with obvious microbial contamination.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some serum specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the serum specimen is centrifuged before a complete clotting, the presence of fibrin may cause erroneous results.
- Samples must be free of fibrin and other particulate matter.
- To prevent cross contamination, use of disposable pipettes or pipette tips is recommended.

Preparation for Analysis

- Inspect all specimens for foam. Remove foam with an applicator stick before analysis. Use a new applicator stick for each specimen to prevent cross contamination.
- Frozen specimens must be completely thawed before mixing. Mix thawed specimens thoroughly by low speed vortexing or by gently inverting. Visually inspect the specimens. If layering or stratification is observed, mix until specimens are visibly homogeneous. If specimens are not mixed thoroughly, inconsistent results may be obtained.
- Specimens should be free of fibrin, red blood cells, or other particulate matter. Such specimens may give reliable results and must be centrifuged prior to testing. Transfer clarified specimen to a sample cup or secondary tube for testing. For centrifuged specimens with a lipid layer, transfer only the clarified specimen and not the lipemic material.
- The sample volume required for a single determination of this assay is 100 μL.

Specimen Storage

Specimens removed from the separator, red blood cells or clot may be stored up to 24 hours at 15-25°C, or 7 days at 2-8°C, or 1 year frozen at -20°C. Frozen specimens subjected to up to 2 freeze/thaw cycles have been evaluated.

Specimen Shipping

- Package and label specimens in compliance with applicable local regulations covering the transport of clinical specimens and infectious substances.
- Do not exceed the storage limitations listed above.

Specimen Dilution

- Samples, PIVKA-II concentrations above the analytical measuring interval, can be diluted with Diluent either automated dilution protocol or manual dilution procedure. The recommended dilution ratio is 1:10. The concentration of the diluted sample must be > 3000 mAU/mL.
- For manual dilution, multiply the result by the dilution factor. For dilution by the analyzers, the analyzer software automatically takes the dilution into account when calculating the sample concentration.

PROCEDURE

Materials Provided

PIVKA-II (CLIA) assay, control barcode labels.

Materials Required (But Not Provided)

- General laboratory equipment.
- Fully-auto chemiluminescence immunoassay analyzer Maglumi 600, Maglumi 800, Maglumi 1000, Maglumi 2000, Maglumi 2000 Plus, Maglumi 4000, Maglumi 4000 Plus, MAGLUMI X8, MAGLUMI X3, MAGLUMI X6, or Integrated System Biolumi 8000 and Biolumi CX8.
- Additional accessories of test required for the above analyzers include Reaction Module, Starter 1+2, Wash Concentrate, Light Check, Tip, and Reaction Cup. Specific accessories and accessories' specification for each model refer to corresponding Analyzer Operating Instructions.
- Please use accessories specified by Snibe to ensure the reliability of the test results.

Assay Procedure

Preparation of the Reagent

- Take the reagent kit out of the box and visually inspect the integral vials for leaking at the sealing film or elsewhere. If there is no leakage, please tear off the sealing film carefully.
- Open the reagent area door; hold the reagent handle to get the RFID label close to the RFID reader (for about 2s); the buzzer will beep; one beep sound indicates successful sensing.
- Keeping the reagent straight insert to the bottom along the blank reagent track.
- Observe whether the reagent information is displayed successfully in the software interface, otherwise repeat the above two steps.
- Resuspension of the magnetic microbeads takes place automatically when the kit is loaded successfully, ensuring the magnetic microbeads are totally resuspended homogenous prior to use.

Assay Calibration

- Select the assay to be calibrated and execute calibration operation in reagent area interface. For specific information on ordering calibrations, refer to the calibration section of Analyzer Operating Instructions.
- Execute recalibration according to the calibration interval required in this package insert.

Quality Control

- When new lot used, check or edit the quality control information.
- Scan the control barcode, choose corresponding quality control information and execute testing. For specific information on ordering quality controls, refer to the quality control section of the Analyzer Operating Instructions.

Sample Testing

- After successfully loading the sample, select the sample in interface and edit the assay for the sample to be tested and execute testing. For specific information on ordering patient specimens, refer to the sample ordering section of the Analyzer Operating Instructions.

To ensure proper test performance, strictly adhere to Analyzer Operating Instructions.

Calibration

Traceability: This method has been standardized against the Snibe internal reference standard.

Test of assay specific calibrators allows the detected relative light unit (RLU) values to adjust the master curve.

Recalibration is recommended as follows:

- Whenever a new lot of Reagent or Starter 1+2 is used.
- Every 7 days.
- The analyzer has been serviced.
- Control values lie outside the specified range.

Quality Control

Controls are recommended for the determination of quality control requirements for this assay and should be run in singlicate to monitor the assay performance. Refer to published guidelines for general quality control recommendations, for example Clinical and Laboratory Standards Institute (CLSI) Guideline C24 or other published

guidelines¹⁵. Quality control is recommended once per day of use, or in accordance with local regulations or accreditation requirements and your laboratory's quality control procedures, quality control could be performed by running the PIVKA-II assay:

- Whenever the kit is calibrated.
- Whenever a new lot of Starter 1+2 or Wash Concentrate is used.

Controls are only applicable with MAGLUMI and Biolumi system and only used matching with the same top seven LOT numbers of corresponding reagents. For each target value and range refer to the label.

The performance of other controls should be evaluated for compatibility with this assay before they are used. Appropriate value ranges should be established for all quality control materials used.

Control values must lie within the specified range, whenever one of the controls lies outside the specified range, calibration should be repeated and controls retested. If control values lie repeatedly outside the predefined ranges after successful calibration, patient results must not be reported and take the following actions:

- Verify that the materials are not expired.
- Verify that required maintenance was performed.
- Verify that the assay was performed according to the package insert.
- If necessary, contact Snibe or our authorized distributors for assistance.

If the controls in kit are not enough for use, please order PIVKA-II (CLIA) Controls (REF: 160201150MT) from Snibe or our authorized distributors for more.

■ RESULTS

Calculation

The analyzer automatically calculates the PIVKA-II concentration in each sample by means of a calibration curve which is generated by a 2-point calibration master curve procedure. The results are expressed in mAU/mL. For further information please refer to the Analyzer Operating Instructions.

Interpretation of Results

The expected range for the PIVKA-II assay was obtained by testing 245 apparently healthy individuals in China, gave the following expected value: ≤40 mAU/mL (95th percentile).

Results may differ between laboratories due to variations in population and test method. It is recommended that each laboratory establish its own reference interval.

■ LIMITATIONS

- Results should be used in conjunction with patient's medical history, clinical examination and other findings.
- If the PIVKA-II results are inconsistent with clinical evidence, additional testing is needed to confirm the result.
- Medication containing vitamin K preparations or analogs may result in lower PIVKA-II values¹⁶.
- Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Such specimens may show either falsely elevated or depressed values when tested with assay kits which employ mouse monoclonal antibodies^{17,18}. Additional information may be required for diagnosis.
- Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with *in vitro* immunoassays. Patients routinely exposed to animals or animal serum products can be prone to this interference and anomalous values may be observed¹⁹.
- Bacterial contamination or heat inactivation of the specimens may affect the test results.

■ SPECIFIC PERFORMANCE CHARACTERISTICS

Representative performance data are provided in this section. Results obtained in individual laboratories may vary.

Precision

Precision was determined using the assay, samples and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): duplicates at two independent runs per day for 5 days at three different sites using three lots of reagent kits (n = 180). The following results were obtained:

Sample	Mean (mAU/mL) (n=180)	Within-Run		Between-Run		Reproducibility	
		SD (mAU/mL)	%CV	SD (mAU/mL)	%CV	SD (mAU/mL)	%CV
Serum Pool 1	41.031	1.529	3.73	0.182	0.44	2.524	6.15
Serum Pool 2	253.155	8.598	3.40	2.829	1.12	12.281	4.85
Serum Pool 3	9936.010	220.772	2.22	128.317	1.29	353.186	3.55
Plasma Pool 1	40.835	1.772	4.34	0.747	1.83	2.236	5.48
Plasma Pool 2	252.531	8.680	3.44	3.104	1.23	10.46	4.25
Plasma Pool 3	9958.046	220.808	2.22	70.833	0.71	296.527	2.98
Control 1	49.411	2.076	4.20	0.577	1.17	3.248	6.57
Control 2	5030.270	140.345	2.79	79.193	1.57	228.632	4.55

Linear Range

5.00-30000 mAU/mL (defined by the Limit of Quantitation and the maximum of the master curve).

Reportable Interval

1.20-300000 mAU/mL (defined by the Limit of Detection and the maximum of the master curve×Recommended Dilution Ratio).

Analytical Sensitivity

Limit of Blank (LoB) =0.500 mAU/mL.
Limit of Detection (LoD) =1.20 mAU/mL.
Limit of Quantitation (LoQ) =5.00 mAU/mL.

Analytical Specificity

Interference

Interference was determined using the assay, three samples containing different concentrations of analyte were spiked with potential endogenous and exogenous interferences in a protocol (EP7-A2) of the CLSI. The measurement deviation of the interference substance is within ±10%. The following results were obtained:

Interference	No interference up to	Interference	No interference up to	Interference	No interference up to
Bilirubin	40 mg/dL	Doxorubicin hydrochloride	1.16 µg/mL	Interferon-γ	3000 IU/mL
Hemoglobin	2000 mg/dL	Methotrexate	45 µg/mL	ascorbic acid	0.5 mg/mL
Intralipid	1000 mg/dL	Bleomycin	100 µg/mL	Ibuprofen	0.4 mg/mL
HAMA	40 ng/mL	Cytarabine	30 µg/mL	Acetaminophen	0.6 mg/mL
Rheumatoid factor	1500 IU/mL	Tamoxifen	60 µg/mL	Acetylsalicylic acid	0.5 mg/mL
ANA	6 (S/CO) strong positive	Mitomycin C	75 µg/mL	Vitamin K	0.09 µg/mL
Carboplatin	500 µg/mL	Vinblastine Sulfate	1.5 µg/mL	Dexamethasone	20 µg/mL
Cisplatin	165 µg/mL	Paclitaxel	3.5 ng/mL	-	-
Cyclophosphamide	500 µg/mL	5-Fluorouracil	500 µg/mL	-	-

Cross-Reactivity

Cross-reactivity was determined using the assay, three samples containing different concentrations of analyte were spiked with potential cross-reactants in a protocol (EP7-A2) of the CLSI. The measurement deviation of the interference substance is within ±10%. The following results were obtained:

Cross-reactant	No interference up to	Cross-reactant	No interference up to	Cross-reactant	No interference up to
AFP	1000 IU/mL	CEA	1000 ng/mL	CA 19-9	500 U/mL
CA 72-4	500 U/mL	HCG	1000 IU/mL	Prothrombin	150 µg/mL

High-Dose Hook

No high-dose hook effect was seen for PIVKA-II concentrations up to 300000 mAU/mL.

Method Comparison

A comparison of the PIVKA-II assay with a commercially available immunoassay, gave the following correlations (mAU/mL):
Number of samples measured: 1051
Passing-Bablok: y=1.0093x-0.1382, r=0.912.

The clinical specimen concentrations were between 6.36 and 29922.27 mAU/mL.

■ REFERENCES

1. Okuda H, Obata H, Nakanishi T, et al. Production of abnormal prothrombin (des-γ-carboxy prothrombin) by hepatocellular carcinoma: A clinical and experimental study [J]. Journal of hepatology, 1987, 4(3): 357-363.
2. Inagaki Y, Tang W, Makuuchi M, et al. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin[J]. Liver International, 2011, 31(1): 22-35.
3. Uehara S, Gotoh K, Handa H, et al. Process of carboxylation of glutamic acid residues in the Gla domain of human des-γ-carboxyprothrombin[J]. Clinica chimica acta,1999, 289 (1): 33-44.
4. Liebman H A, Furie B C, Tong M J, et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma[J]. New England Journal of Medicine, 1984, 310(22): 1427-1431.
5. Ferland G, Sadowski J A, Obrien M E, et al. Dietary induced subclinical vitamin K deficiency in normal human subjects [J]. Journal of Clinical Investigation, 1993, 91(4): 1761-1768.
6. Lee W, Chung H J, Kim S, et al. PIVKA-II is a candidate marker for monitoring the effects of the oral anticoagulant warfarin[J]. Clinical Biochemistry, 2010, 43(13-14):1177-1179.
7. Widdershoven J, Van Munster P, De Abreu R, et al. Four methods compared for measuring des-carboxy-prothrombin (PIVKA-II)[J]. Clinical chemistry, 1987, 33(11): 2074-2078.
8. Okuda H, Nakanishi T, Takatsu K, et al. Measurement of serum levels of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity [J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 1999, 85(4): 812-818.
9. Volk M L, Hernandez J C, Su G L, et al. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3 [J]. Cancer Biomarkers, 2007, 3(2): 79-87.
10. Yu R, Xiang X, Tan Z, et al. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients [J]. Scientific Reports, 2016, 6(1).
11. Yu R, Tan Z, Xiang X, et al. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data[J]. BMC Cancer, 2017, 17(1):608.
12. Park H, Park J Y. Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma.[J]. BioMed Research International, 2013: 310427-310427.
13. Saitta C Saitta C, Raffa G, Alibrandi A, et al. PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients.[J]. Medicine, 2017, 96(26).
14. Volk M L, Hernandez J C, Su G L, et al. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3 [J]. Cancer Biomarkers, 2007, 3(2): 79-87.
15. CLSI. Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions. 4th ed. CLSI guideline C24. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
16. Ishizuka M, Kubota K, Shimoda M, et al. Effect of Menatetrenone, a Vitamin K2 Analog, on Recurrence of Hepatocellular Carcinoma after Surgical Resection: A Prospective Randomized Controlled Trial [J]. Anticancer Research, 2012, 32(12): 5415-5420.
17. Robert W. Schroff, Kenneth A. Foon, Shannon M. Beatty, et al. Human Anti-Murine Immunoglobulin Responses in Patients Receiving Monoclonal Antibody Therapy [J]. Cancer Research, 1985, 45(2):879-885.
18. Primus F J, Kelley E A, Hansen H J, et al. "Sandwich"-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy [J]. Clinical Chemistry, 1988, 34(2):261-264.
19. Boscato L M, Stuart M C. Heterophilic antibodies: a problem for all immunoassays [J]. Clinical Chemistry, 1988, 34 (1):27-33.

■ SYMBOLS EXPLANATIONS

	Consult instructions for use		Manufacturer
	Temperature limit (Store at 2-8 °C)		Use-by date
	Contains sufficient for<n> tests		Keep away from sunlight
	This way up		Authorized representative in the European Community
	<i>In vitro</i> diagnostic medical device		Kit component
	Catalogue number		Batch code
	CE marking with notified body ID number		

MAGLUMI® and Biolumi® are trademarks of Snibe. All other product names and trademarks are the property of their respective owners.

Summary of safety and performance is available at Eudamed.



Shenzhen New Industries Biomedical Engineering Co., Ltd.
No.23, Jinxiu East Road, Pingshan District, 518122 Shenzhen, P.R. China
Tel: +86-755-21536601 Fax: +86-755-28292740



Shanghai International Holding Corp. GmbH (Europe)
Eiffelstrasse 80, 20537 Hamburg, Germany
Tel: +49-40-2513175 Fax: +49-40-255726